共 214 条
[1]
Bardia A(2021)Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer N Engl J Med 384 1529-1541
[2]
Hurvitz SA(2022)Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences Explor Target Antitumor Ther 3 763-794
[3]
Tolaney SM(2016)Cost-effectiveness thresholds: pros and cons Bull World Health Organ 94 925-930
[4]
Loirat D(2020)Cancer burden of major cancers in China: a need for sustainable actions Cancer Commun (lond) 40 205-210
[5]
Punie K(2018)Pharmacoeconomics of three Therapeutic Schemes for Anti-tuberculosis Therapy Induced Liver Injury in China Open Med (wars) 13 53-63
[6]
Oliveira M(2022)Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer N Engl J Med 386 1143-1154
[7]
Brufsky A(2015)Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective Clinicoecon Outcomes Res 7 249-256
[8]
Sardesai SD(2021)HER2-positive metastatic breast cancer: a comprehensive review Clin Adv Hematol Oncol 19 40-50
[9]
Kalinsky K(2017)Changing global policy to deliver safe, equitable, and affordable care for women's cancers Lancet 389 871-880
[10]
Zelnak AB(2012)Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves BMC Med Res Methodol 12 9-1150